## A randomized, double blind, comparative trial of micafu the treatment of oesophageal candidiasis

Alimentary Pharmacology and Therapeutics 21, 899-907 DOI: 10.1111/j.1365-2036.2005.02427.x

**Citation Report** 

#	Article	IF	CITATIONS
1	Fungal infection. Current Anaesthesia and Critical Care, 2005, 16, 231-241.	0.3	8
2	The Pharmacokinetics and Safety of Micafungin, a Novel Echinocandin, in Premature Infants. Pediatric Infectious Disease Journal, 2006, 25, 1110-1115.	1.1	167
3	Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. Journal of Infection, 2006, 53, 337-349.	1.7	290
4	New antifungal therapies. Clinical Microbiology Newsletter, 2006, 28, 169-173.	0.4	2
6	Micafungin sodium, the second of the echinocandin class of antifungals: theory and practice. Future Microbiology, 2006, 1, 161-170.	1.0	14
7	A Multicenter Randomized Trial Evaluating Posaconazole versus Fluconazole for the Treatment of Oropharyngeal Candidiasis in Subjects with HIV/AIDS. Clinical Infectious Diseases, 2006, 42, 1179-1186.	2.9	171
8	Micafungin: A New Echinocandin. Clinical Infectious Diseases, 2006, 42, 1171-1178.	2.9	221
9	Echinocandins in the management of invasive fungal infections, part 1. American Journal of Health-System Pharmacy, 2006, 63, 1693-1703.	0.5	68
10	Developments in the treatment of candidiasis: more choices and new challenges. Expert Opinion on Investigational Drugs, 2006, 15, 1319-1336.	1.9	48
11	Reviews Of Antiâ€infective Agents: New Agents for the Treatment of Fungal Infections: Clinical Efficacy and Gaps in Coverage. Clinical Infectious Diseases, 2006, 43, 1060-1068.	2.9	148
12	Clinical efficacy of micafungin for chronic pulmonary aspergillosis. Medical Mycology, 2007, 45, 273-278.	0.3	35
13	Update on New Antifungal Therapy. AACN Advanced Critical Care, 2007, 18, 253-260.	0.6	4
14	Fungal Genetics, Genomics, and Secondary Metabolites in Pharmaceutical Sciences. Planta Medica, 2007, 73, 103-115.	0.7	49
15	Antifungal Therapy in Children With Invasive Fungal Infections: A Systematic Review. Pediatrics, 2007, 119, 772-784.	1.0	79
16	Update on New Antifungal Therapy. AACN Advanced Critical Care, 2007, 18, 253-260.	0.6	6
17	Nongastroesophageal reflux disease-related infectious, inflammatory and injurious disorders of the esophagus. Current Opinion in Internal Medicine, 2007, 6, 473-478.	1.5	5
18	27 Antifungal drugs. Side Effects of Drugs Annual, 2007, 29, 280-293.	0.6	0
19	Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet, The, 2007, 369, 1519-1527.	6.3	1,185

ARTICLE IF CITATIONS # Clinical pharmacology of antifungal agents in pediatric patients. Expert Opinion on Pharmacotherapy, 21 0.9 20 2007, 8, 2465-2489. A comparative evaluation of properties and clinical efficacy of the echinocandins. Expert Opinion on Pharmacotherapy, 2007, 8, 1479-1492. The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy 23 0.9 53 and safety. Expert Opinion on Pharmacotherapy, 2007, 8, 1155-1166. Recent advances in antifungal chemotherapy. International Journal of Antimicrobial Agents, 2007, 30, 24 108-117. Micafungin: A New Echinocandin Antifungal. Pharmacotherapy, 2007, 27, 53-67. 25 1.2 56 The Echinocandins. Pharmacotherapy, 2007, 27, 369-388. 1.2 Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation. International Journal of Hematology, 2008, 88, 588-595. 27 0.7 73 Early Clinical Experience with Anidulafungin at a Large Tertiary Care Medical Center. 1.2 Pharmacotherapy, 2008, 28, 64-73. 30 Current Options in Antifungal Pharmacotherapy. Pharmacotherapy, 2008, 28, 614-645. 1.2 68 Micafungin. Drugs, 2008, 68, 2225-2255. Management of fungal infections following allogeneic stem cell transplantation. Expert Review of 33 2.0 0 Anti-Infective Therapy, 2008, 6, 373-384. Oesophageal Candidiasis in Elderly Patients. Drugs and Aging, 2008, 25, 119-130. 1.3 Advances in Antifungal Therapy. Annual Review of Medicine, 2008, 59, 361-379. 35 5.0 68 Single-dose pharmacokinetics of the cholesteryl sulfate complex of amphotericin B in critically ill patients with cholestatic liver failure. Critical Care, 2008, 12, P23. 2.5 Analytical survey of human rabies and animal bite prevalence during one decade in the province of 37 2.51 Kerman, Iran. Critical Care, 2008, 12, P1. What do people really know about MRSA? A survey of knowledge and attitudes in the general public and hospital visitors. Critical Care, 2008, 12, P2. 39 Intensive care infections: risk factors and mortality. Critical Care, 2008, 12, P3. 2.5 0 Gram-positive nosocomial infections in a general ICU: searching for a clue. Critical Care, 2008, 12, P4.

~	_
(ITAT	Report
CIAL	REFORT

#	Article	IF	CITATIONS
41	Descriptive analysis of ICU patients with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia at four academic medical centers. Critical Care, 2008, 12, P5.	2.5	0
42	European multicenter survey on antibiotic prophylaxis in liver transplant patients. Critical Care, 2008, 12, P6.	2.5	2
43	A national survey on current practice of use of selective digestive decontamination in the United Kingdom. Critical Care, 2008, 12, P7.	2.5	6
44	Community-acquired and healthcare-related urosepsis: a multicenter prospective study. Critical Care, 2008, 12, P8.	2.5	2
45	Bedside laparoscopy to diagnose intrabdominal pathology in the ICU. Critical Care, 2008, 12, P9.	2.5	0
46	A potential role for the chest X-ray in the transmission of resistant bacteria in the ICU. Critical Care, 2008, 12, P10.	2.5	0
47	Healthcare-related bacteraemia admitted to the ICU. Critical Care, 2008, 12, P11.	2.5	0
48	Incidence of nosocomial infection in patients with nontraumatic or traumatic coma. Critical Care, 2008, 12, P12.	2.5	1
49	Comparative study on infection of the central nervous system in patients with head trauma and spontaneous cerebral hemorrhage. Critical Care, 2008, 12, P13.	2.5	2
50	Respiratory community-acquired and healthcare-related sepsis: are they different?. Critical Care, 2008, 12, P14.	2.5	0
51	Antibiotic costs in bacteremic and nonbacteremic patients treated with the de-escalation approach. Critical Care, 2008, 12, P15.	2.5	1
52	When appropriate antibiotic therapy is relevant in bacteremic septic patients. Critical Care, 2008, 12, P16.	2.5	0
53	Incidence of candidemia before and after fluconazole prophylaxis implementation in a 14-bed general ICU. Critical Care, 2008, 12, P17.	2.5	0
54	Comparison between mortality and airway colonisation versus noncolonisation with Candida species in critically ill adults. Critical Care, 2008, 12, P18.	2.5	0
55	Risk factors for lung colonization by Candida albicans in a general ICU. Critical Care, 2008, 12, P19.	2.5	1
56	Combination therapy with efungumab for the treatment of invasive Candida infections: several illustrative case reports. Critical Care, 2008, 12, P20.	2.5	3
57	Pooled analysis of safety for micafungin. Critical Care, 2008, 12, P21.	2.5	3
58	Pharmacokinetics of micafungin in adult patients with invasive candidiasis and candidaemia. Critical Care, 2008, 12, P22.	2.5	0

#	Article	IF	CITATIONS
59	Serum tobramycin levels during selective decontamination of the digestive tract in ICU patients on renal replacement therapy. Critical Care, 2008, 12, P24.	2.5	0
60	The pharmacokinetics of dalbavancin in subjects with mild, moderate, or severe hepatic impairment. Critical Care, 2008, 12, P25.	2.5	1
61	Dalbavancin dosage adjustments not required for patients with mild to moderate renal impairment. Critical Care, 2008, 12, P26.	2.5	0
62	Dalbavancin safety in the phase 2/3 clinical development program. Critical Care, 2008, 12, P27.	2.5	0
63	Efficacy of telavancin for treatment of surgical site infections. Critical Care, 2008, 12, P28.	2.5	0
64	Recurrence of skin infections in patients treated with telavancin versus vancomycin for complicated skin and soft tissue infections in a New Orleans emergency department. Critical Care, 2008, 12, P29.	2.5	2
65	Daptomycin therapy for Gram-positive bacterial infections: a retrospective study of 30 cardiac surgery patients. Critical Care, 2008, 12, P30.	2.5	0
66	Therapy with teicoplanin in the ICU: continuous intravenous infusion or intermittent intravenous administration?. Critical Care, 2008, 12, P31.	2.5	1
67	Bacterial population and antibiotic resistance in an ICU during a 4-year period. Critical Care, 2008, 12, P32.	2.5	0
68	Relationship of microorganism carriage and infections in ICU patients. Critical Care, 2008, 12, P33.	2.5	0
69	Rifampicin and colistin association in the treatment of severe multiresistant Acinetobacter baumannii infections. Critical Care, 2008, 12, P34.	2.5	0
70	Trends of resistance of Gram-negative bacteria in the ICU during a 3-year period. Critical Care, 2008, 12, P35.	2.5	0
71	Colonization and infection by potential Gram-negative multiresistant microorganism in a medical–surgical ICU. Critical Care, 2008, 12, P36.	2.5	1
72	Changing resistance pattern for Acinetobacter baumannii through the years. Critical Care, 2008, 12, P37.	2.5	0
73	Catheter-related bloodstream infection according to central venous accesses. Critical Care, 2008, 12, P38.	2.5	1
74	Comparison of oligon central venous catheters with standard multilumen central venous catheters in cardiac surgery ICU patients. Critical Care, 2008, 12, P39.	2.5	0
75	A multicenter randomized controlled clinical trial comparing central venous catheters impregnated with either 5-fluorouracil or chlorhexidine/silver sulfadiazine in preventing catheter colonization. Critical Care, 2008, 12, P40.	2.5	4
76	High epithelial lining fluid concentrations of NKTR-061 (inhaled amikacin) twice daily achieved in pneumonic portions of lung. Critical Care, 2008, 12, P41.	2.5	0

ARTICLE IF CITATIONS # NKTR-061 (inhaled amikacin) delivers high lung doses in mechanically ventilated patients with 77 2.5 6 pneumonia and in healthy subjects. Critical Care, 2008, 12, P42. Ten-year exploratory retrospective study on empyema. Critical Care, 2008, 12, P43. 2.5 Validation of predictive rules for ICU patients with community-acquired pneumonia. Critical Care, 79 2.50 2008, 12, P44. Effect of age on resolution of ventilator-associated pneumonia. Critical Care, 2008, 12, P45. 2.5 An endotracheal tube with a polyurethane cuff and subglottic secretion drainage reduces the incidence of primary and secondary endogenous ventilator-associated pneumonia. Critical Care, 2008, 81 2.5 1 12, P46. Effect of continuous aspiration of subglottic secretions on the prevention of ventilator-associated pneumonia in mechanically ventilated patients. Critical Care, 2008, 12, P47. 2.5 Effect of an oral care protocol in preventing ventilator-associated pneumonia in ICU patients. Critical 83 2.5 4 Care, 2008, 12, P48. Soluble triggering receptor expressed on myeloid cells-1 in bronchoalveolar lavage is not predictive 84 2.5 for ventilator-associated pneumonia. Critical Care, 2008, 12, P49. Ventilator-associated pneumonia in an ICU: epidemiology, etiology and comparision of two 85 2.5 0 bronchoscopic methods for microbiological specimen sampling. Critical Care, 2008, 12, P50. Presence of human metapneumovirus in bronchoalveolar lavage fluid samples detected by means of 2.5 real-time polymerase chain reaction. Critical Care, 2008, 12, P51. Prebiotic, probiotic and synbiotic usage and gastrointestinal and trachea colonization in 87 0 2.5 mechanically ventilated patients. Critical Care, 2008, 12, P52. Comparison of the surveillance with quantitative and nonquantitative ETA cultures in predicting ventilator-associated pneumonia etiology in patients receiving antibiotic therapy. Critical Care, 2008, 2.5 12, P53. Errors regarding specific preventive measures of ventilator-associated pneumonia in the ICU. Critical 89 2.5 0 Care, 2008, 12, P54. Clinical predictors for septic shock in patients with ventilator-associated pneumonia. Critical Care, 2.5 2008, 12, P55. Antibiotic-related acute effects within the intestinal microcirculation in experimental sepsis. Critical 91 2.51 Care, 2008, 12, P56. Intraperitoneal lipopolysaccharide-induced neutrophil sequestration in the lung microvasculature is due to a factor produced in the peritoneal cavity. Critical Care, 2008, 12, P57. Correlation between microcirculatory flow, density and heterogeneity scores in septic shock 93 2.50 patients. Critical Care, 2008, 12, P58. Effect of iloprost on the microcirculation and liver function after orthotopic liver transplantation. 94 Critical Care, 2008, 12, P59.

#	Article	IF	CITATIONS
95	Noninvasive monitoring of peripheral perfusion with physical examination and the peripheral flow index correlates with dynamic near-infrared spectroscopy measurements in patients with septic shock. Critical Care, 2008, 12, P60.	2.5	2
96	Effect of intravenous nitroglycerin on the sublingual microcirculation in patients admitted to the intensive cardiac care unit. Critical Care, 2008, 12, P61.	2.5	0
97	Relationship between the sublingual microcirculation and lactate levels in patients with heart failure. Critical Care, 2008, 12, P62.	2.5	1
98	Sidestream dark-field imaging versus orthogonal polarization spectroscopic imaging: a comparative study. Critical Care, 2008, 12, P63.	2.5	2
99	Finger reactive hyperaemia to measure endothelial function in sepsis and health (the FRESH study). Critical Care, 2008, 12, P64.	2.5	1
100	Microcirculatory investigation in severe trauma injury. Critical Care, 2008, 12, P65.	2.5	0
101	Assessment of tissue hypoperfusion by subcutaneous microdialysis during septic shock: cases with bacteremia versus nonbacteremia. Critical Care, 2008, 12, P66.	2.5	1
102	Tissue perfusion evaluation with near-infrared spectroscopy during treatment with activated protein C. Critical Care, 2008, 12, P67.	2.5	0
103	Tissue oxygen saturation does not correlate with the oxygen delivery index during major abdominal surgery. Critical Care, 2008, 12, P68.	2.5	0
104	Near-infrared spectroscopy as a potential surrogate for mixed venous oxygen saturation for evaluation of patients with hemodynamic derangements. Critical Care, 2008, 12, P69.	2.5	3
105	Changes in thenar eminence tissue oxygen saturation measured using near-infrared spectroscopy suggest ischaemic preconditioning in a repeated arterial occlusion forearm ischaemia model. Critical Care, 2008, 12, P70.	2.5	1
106	Tissue oxygen saturation during anaesthesia, cardiopulmonary bypass and intensive care stay for cardiac surgery. Critical Care, 2008, 12, P71.	2.5	0
107	Near-infrared spectroscopy during stagnant ischemia: a marker of ScvO2–SvO2 mismatch in septic patients with low cardiac output. Critical Care, 2008, 12, P72.	2.5	0
108	Relationship between central venous oxygen saturation measured in the inferior and superior vena cava. Critical Care, 2008, 12, P73.	2.5	0
109	Early worst central venous oxygen saturation is predictive of mortality in severe head trauma but not in moderate head trauma. Critical Care, 2008, 12, P74.	2.5	3
110	Comparison between continuous and discontinuous central venous oxygen saturation in the ICU: a prospective study and preliminary results. Critical Care, 2008, 12, P75.	2.5	0
111	Influence of tissue perfusion on the outcome of high-risk surgical patients needing blood transfusion. Critical Care, 2008, 12, .	2.5	0
112	Hyperlactatemia and low central venous saturation can predict prognosis after cardiac surgery. Critical Care, 2008, 12, .	2.5	0

#	Article	IF	CITATIONS
113	Clinical utility of arterialised capillary earlobe sampling in the critical care setting. Critical Care, 2008, 12, P78.	2.5	3
114	Emergent internal jugular vein cannulation as a risk factor associated with arterial puncture. Critical Care, 2008, 12, P79.	2.5	1
115	Use of ultrasound for central venous catheter placement. Critical Care, 2008, 12, P80.	2.5	1
116	Is there a 'safe mean airways pressure' in preterm babies with hyaline membrane disease: an echocardiographic retrospective approach. Critical Care, 2008, 12, P81.	2.5	Ο
117	Right ventricular dysfunction in liver failure: a hemodynamic study. Critical Care, 2008, 12, P82.	2.5	2
118	Diastolic function abnormalities in ICU patients with chronic obstructive pulmonary disease. Critical Care, 2008, 12, P83.	2.5	0
119	Noninvasive rodent cardiac output: comparison of a compact clinical monitor with echocardiography and proposal of a simple correction factor. Critical Care, 2008, 12, P84.	2.5	0
120	Prospective, observational study of the reliability of achieving diagnostic quality transthoracic echocardiograpy images in critically ill adult patients. Critical Care, 2008, 12, P85.	2.5	0
121	Evaluation of bedside lung ultrasonography in the diagnosis of alveolar-interstitial syndrome and pleural effusion in the ICU. Critical Care, 2008, 12, P86.	2.5	0
122	Measurement of vena cava inferior diameter in hemorrhagic shock diagnosis. Critical Care, 2008, 12, P87.	2.5	2
123	Arterial pressure changes during the Valsalva maneuver to predict fluid responsiveness in spontaneously breathing patients. Critical Care, 2008, 12, P88.	2.5	1
124	Passive leg raising predicts fluid responsiveness after cardiac surgery. Critical Care, 2008, 12, .	2.5	0
125	Variation of hemodynamic parameters after fluid challenge. Critical Care, 2008, 12, P90.	2.5	2
126	Comparison of pulse pressure variation and end-diastolic volume index in an experimental model of hemorrhagic shock in the pig. Critical Care, 2008, 12, .	2.5	0
127	Evaluation of systolic pressure variation and pulse pressure variation in an experimental model of acute normovolemic hemodilution. Critical Care, 2008, 12, .	2.5	0
128	Venous return in ICU patients. Critical Care, 2008, 12, P93.	2.5	2
129	Prediction of fluid responsiveness by FloTracâ"¢ and PiCCOplusâ"¢ in cardiac surgery patients. Critical Care, 2008, 12, P94.	2.5	0
130	Myocardial dysfunction in sepsis studied with the pressure recording analytical method. Critical Care, 2008, 12, P95.	2.5	0

#	Article	IF	CITATIONS
т 131	TruCCOMS: real-time continuous cardiac output?. Critical Care, 2008, 12, P96.	2.5	0
101		2.0	0
132	Evaluation of a modified FloTracâ,,¢ algorithm for cardiac output measurement in cardiac surgery patients. Critical Care, 2008, 12, P97.	2.5	0
133	Reliability of continuous pulse contour cardiac output measurement. Critical Care, 2008, 12, P98.	2.5	0
134	Indication of peripheral decoupling during extreme hyperdynamic conditions in septic patients. Critical Care, 2008, 12, P99.	2.5	0
135	How accurate are different arterial pressure-derived estimates of cardiac output and stroke volume variation measures in critically ill patients?. Critical Care, 2008, 12, P100.	2.5	0
136	Uncalibrated arterial pulse contour analysis in major vascular surgery. Critical Care, 2008, 12, P101.	2.5	Ο
137	Comparison of Niccomoâ,"¢ bioimpedance cardiac output with lithium dilution (LIDCOâ,"¢) in ICU patients. Critical Care, 2008, 12, P102.	2.5	1
138	Intrathoracic blood volume measurement: comparison of transpulmonary lithium indicator dilution with indocyanine green indicator dilution. Critical Care, 2008, 12, P103.	2.5	Ο
139	Global end-diastolic volume as an indicator of cardiac preload in hemorrhagic shock and resuscitation in swine. Critical Care, 2008, 12, P104.	2.5	0
140	Prognostic value of the extravascular lung water index in critically ill septic shock patients. Critical Care, 2008, 12, P105.	2.5	Ο
141	Conjunctival microcirculation in patients with traumatic brain injury. Critical Care, 2008, 12, P106.	2.5	2
142	Novel models for the prediction of mortality after traumatic brain injury requiring intensive care. Critical Care, 2008, 12, P107.	2.5	Ο
143	Changes in cerebral physiology following cranioplasty: a 15oxygen positron emission tomography study. Critical Care, 2008, 12, P108.	2.5	0
144	Brain tissue oxygenation: more than a number. Critical Care, 2008, 12, P109.	2.5	1
145	Fatty acid binding protein and tau levels are related to brain damage and outcome after subarachnoid hemorrhage. Critical Care, 2008, 12, P110.	2.5	0
146	Transdermal nicotine replacement is associated with lower mortality among active smokers admitted with spontaneous subarachnoid hemorrhage. Critical Care, 2008, 12, P111.	2.5	2
147	Impact of treatment with pravastatin on delayed ischemic disease and mortality after aneurysmal subarachnoid hemorrhage. Critical Care, 2008, 12, P112.	2.5	15
148	Pentraxin 3 as a marker of vasospasm following subarachnoid hemorrhage. Critical Care, 2008, 12, P113.	2.5	0

#	Article	IF	CITATIONS
149	Transcranial sonography investigations of the cerebral blood flow disturbances after hypothalamic pituitary and brain stem surgery. Critical Care, 2008, 12, P114.	2.5	0
150	Flow velocity in head injury of different severity: findings of transcranial duplex sonography. Critical Care, 2008, 12, P115.	2.5	0
151	Transcranial Doppler in serious malaria. Critical Care, 2008, 12, P116.	2.5	0
152	Noninvasive assessment of intracranial pressure using ocular sonography in neurocritical care patients. Critical Care, 2008, 12, P117.	2.5	7
153	Clinical and prognostic role of intracranial pressure monitoring in patients with aneurismal subarachnoid haemorrhage. Critical Care, 2008, 12, P118.	2.5	0
154	Electroencephalogram desynchronization in brain trauma patients. Critical Care, 2008, 12, P119.	2.5	1
155	Effects of mannitol and melatonin on magnetic resonance imaging findings in secondary brain damage. Critical Care, 2008, 12, P120.	2.5	0
156	Brain trauma care targets analysis using a high-rate recording and computing network. Critical Care, 2008, 12, P121.	2.5	0
157	Audit of compliance with ventilation protocol in severe head injuries: a retrospective study. Critical Care, 2008, 12, P122.	2.5	0
158	c-Jun N-terminal kinase pathway activation in human and experimental traumatic brain injury: neuroprotective effects of its inhibition. Critical Care, 2008, 12, P123.	2.5	0
159	Hormones and cytokines as biomarkers for immediate cure measures in severe neurosurgical patients: base for inclusion in a neuromonitoring algorithm. Critical Care, 2008, 12, P124.	2.5	1
160	Is the ratio of lactated to pyrostaphylic acid in cerebral tissue a prognostic index for the outcome of patients with intracerebral hemorrhage?. Critical Care, 2008, 12, P125.	2.5	0
161	Coagulopathy predicts poor outcome in traumatic brain injury. Critical Care, 2008, 12, P126.	2.5	1
162	Alteplase for acute ischemic stroke: 2 years in a community hospital without previous experience in stroke thrombolysis. Critical Care, 2008, 12, P127.	2.5	0
163	Acute lung injury in a neurosciences critical care unit. Critical Care, 2008, 12, P128.	2.5	0
164	Hemodynamic changes after hypothalamic and brain stem surgery: interdisciplinary approach to studying. Critical Care, 2008, 12, P129.	2.5	0
165	Evaluation of development of diabetes insipidus in the early phase following traumatic brain injury in critically ill patients. Critical Care, 2008, 12, P130.	2.5	6
166	Hypernatremia and mortality in patients with severe traumatic brain injury. Critical Care, 2008, 12, P131.	2.5	0

#	Article	IF	Citations
167	Gastric tubes in patients with severe brain injury. Critical Care, 2008, 12, P132.	2.5	1
168	Alcohol: a risk factor for head injury. Critical Care, 2008, 12, P133.	2.5	1
169	Existence of microalbuminuria during evolution of acute coronary syndrome is a powerful short-term and long-term prognostic factor. Critical Care, 2008, 12, P134.	2.5	1
170	Nonoperative management of blunt trauma in abdominal solid organ: a prospective study to evaluate the success rate and predictive factors of failure. Critical Care, 2008, 12, P135.	2.5	1
171	Evidence for early presence of intestinal epithelial cell damage in multitrauma patients. Critical Care, 2008, 12, P136.	2.5	0
172	ICU predictors of morbidity after major trauma. Critical Care, 2008, 12, P137.	2.5	0
173	Hospital mortality and length of ICU stay in severely burned patients. Critical Care, 2008, 12, P138.	2.5	0
174	Sympathetic responses during hemorrhagic shock. Critical Care, 2008, 12, P139.	2.5	0
175	Metabolic evaluation during weaning from mechanical ventilation using indirect calorimetry. Critical Care, 2008, 12, P140.	2.5	1
176	Hypocaloric nutrition and outcome in critically ill patients with prolonged ICU stay. Critical Care, 2008, 12, P141.	2.5	0
177	Early introduction of enteral feeding for patients with percutaneous cardiopulmonary support. Critical Care, 2008, 12, P142.	2.5	0
178	Nutritional activation of the cholinergic pathway after hemorrhagic shock reduces inflammation and preserves intestinal integrity. Critical Care, 2008, 12, P143.	2.5	0
179	Inflammatory response in patients requiring parenteral nutrition: comparison of a new fish-oil-containing emulsion (SMOF®) versus an olive/soybean oil-based formula. Critical Care, 2008, 12, P144.	2.5	8
180	Lipid-enriched nutrition reduces inflammation via local activation of the autonomic nervous system by cholecystokinin. Critical Care, 2008, 12, P145.	2.5	0
181	Efficacy of glutamine dipeptide-supplemented total parenteral nutrition in critically ill patients: a prospective, double-blind randomized trial. Critical Care, 2008, 12, P146.	2.5	0
182	Arginine reduces leukocyte/endothelial cell interaction in a model of normotensive endotoxemia without attenuating capillary perfusion failure. Critical Care, 2008, 12, P147.	2.5	0
183	Antioxidant intake by intensive care patients. Critical Care, 2008, 12, P148.	2.5	0
184	Influence of first glycemia determination in acute coronary syndrome: long-term prognosis. Critical Care, 2008, 12, P149.	2.5	0

#	Article	IF	CITATIONS
185	Tight blood glucose control decreases surgical wound infection in the cardiac surgical patient population in the ICU. Critical Care, 2008, 12, P150.	2.5	0
186	Mechanisms of kidney protection by intensive insulin therapy during critical illness. Critical Care, 2008, 12, P151.	2.5	0
187	Complement activation after uncomplicated coronary artery bypass grafting: role of strict glucose control. Critical Care, 2008, 12, P152.	2.5	1
188	Relationship between admission blood glucose level and prognosis in acute ischemic and hemorrhagic stroke patients. Critical Care, 2008, 12, P153.	2.5	0
189	Significance of the suppression of blood glucose variability in acutely ill severe patients with glucose intolerance evaluated by means of bedside-type artificial pancreas. Critical Care, 2008, 12, P154.	2.5	2
190	Implementing intensive insulin therapy in daily practice reduces the incidence of critical illness polyneuropathy and/or myopathy. Critical Care, 2008, 12, P155.	2.5	1
191	Evaluation of the implementation of a fully automated algorithm (eMPC) in an interacting infusion pump system for the establishment of tight glycaemic control in medical ICU patients. Critical Care, 2008, 12, P156.	2.5	0
192	Tight glucose control by intensive insulin therapy in Belgian ICU: an evaluation of practice. Critical Care, 2008, 12, P157.	2.5	3
193	Glucose control and the incidence of severe hypoglycaemia in a burns population following the introduction of intensive insulin therapy. Critical Care, 2008, 12, P158.	2.5	0
194	Achieving glycemic control with intensive insulin therapy in the ICU. Critical Care, 2008, 12, P159.	2.5	0
195	Intensive insulin therapy: protocols in use in The Netherlands. Critical Care, 2008, 12, P160.	2.5	0
196	Serum insulin-like growth factor binding protein 1 and C-peptide to assess insulin resistance in septic patients. Critical Care, 2008, 12, P161.	2.5	0
197	Insulin increases deformation-induced lung cell death. Critical Care, 2008, 12, P162.	2.5	1
198	Factors influencing accuracy of blood glucose measurements in critically ill patients. Critical Care, 2008, 12, P163.	2.5	0
199	Evaluation of a noninvasive blood glucose monitoring device for critically ill patients. Critical Care, 2008, 12, P164.	2.5	0
200	Evaluation of a near-infrared automated blood glucose monitor for use in critical care settings. Critical Care, 2008, 12, P165.	2.5	2
201	Comparison of accuracy of three point-of-care glucometers in an adult ICU. Critical Care, 2008, 12, P166.	2.5	1
202	Accuracy of point-of-care blood glucose measurements in the medical ICU. Critical Care, 2008, 12, P167.	2.5	Ο

# 203	ARTICLE Tight glycemic control: comparison of a real-time continuous interstitial tissue glucose monitoring system with arterial plasma glucose measurement in critically ill patients. Critical Care, 2008, 12, P168.	IF 2.5	CITATIONS
204	Lactate measurement by the capillary method in shocked patients. Critical Care, 2008, 12, P169.	2.5	0
205	Influence of Stewart acid–base variables on plasma pH in critically ill patients. Critical Care, 2008, 12, P170.	2.5	0
206	Value of postoperative C-reactive protein and leukocyte count after elective thoracoabdominal aneurysm surgery. Critical Care, 2008, 12, P171.	2.5	0
207	Role of inflammation in nonhemorrhagic strokes. Critical Care, 2008, 12, P172.	2.5	0
208	Biomarkers that might improve prognostic accuracy in ICU patients. Critical Care, 2008, 12, P173.	2.5	0
209	Plasma C-reactive protein and albumin as predictors of readmission to intensive care. Critical Care, 2008, 12, P174.	2.5	0
210	Role of the leukocyte antisedimentation rate in prediction of early recognition of post-stroke infection. Critical Care, 2008, 12, P175.	2.5	0
211	Identifying sepsis in the emergency room: the best clinical and laboratory variables. Critical Care, 2008, 12, P176.	2.5	0
212	Procalcitonin, cytokine and NOx in diabetic ketoacidosis. Critical Care, 2008, 12, P177.	2.5	1
213	Assessment of procalcitonin values in deep mycosis associated with high β-D-glucan values. Critical Care, 2008, 12, P178.	2.5	0
214	Elevation of procalcitonin in chronic dialysed patients. Critical Care, 2008, 12, P179.	2.5	1
215	Role of procalcitonin in diagnostics of acute adrenal insufficiency. Critical Care, 2008, 12, P180.	2.5	0
216	Use of procalcitonin as an aid to antibiotic prescribing in intensive care. Critical Care, 2008, 12, P181.	2.5	0
217	Procalcitonin to guide length of antibiotic therapy in surgical intensive care patients. Critical Care, 2008, 12, P182.	2.5	0
218	Validation of procalcitonin measurement to the side of the stream bed as marking infection in intensive therapy patients. Critical Care, 2008, 12, P183.	2.5	0
219	Prognostic value of raised procalcitonin when combined with routine biomarkers of sepsis among critically ill patients. Critical Care, 2008, 12, P184.	2.5	0
220	Procalcitonin in elective colorectal surgery and its predictive value for an early discharge of fast-track patients. Critical Care, 2008, 12, P185.	2.5	1

	CITATION	REFORT	
#	Article	IF	CITATIONS
221	Endotoxin adsorption method may affect serum procalcitonin. Critical Care, 2008, 12, P186.	2.5	1
222	Discriminative procalcitonin values for diagnosis of systemic inflammatory response syndrome and sepsis in the ICU. Critical Care, 2008, 12, P187.	2.5	0
223	Measurement of procalcitonin in bronchoalveolar lavage and serum as early predictors in acute respiratory distress syndrome. Critical Care, 2008, 12, P188.	2.5	0
224	Correlation of endotoxin, procalcitonin and C-reactive peptide patterns with ICU admission. Critical Care, 2008, 12, P189.	2.5	2
225	Why measure endotoxin in septic shock patients?. Critical Care, 2008, 12, P190.	2.5	2
226	Measuring endotoxin with newly developed endotoxin scattering photometry. Critical Care, 2008, 12, P191.	2.5	0
227	Biochemical markers of the iron metabolism and their relationship with the inflammatory status in multiple trauma patients. Critical Care, 2008, 12, P192.	2.5	1
228	Compartmentalization of the inflammatory response in abdominal sepsis. Critical Care, 2008, 12, P193.	2.5	0
229	Early elevation of plasma soluble CD14 subtype, a novel biomarker for sepsis, in a rabbit cecal ligation and puncture model. Critical Care, 2008, 12, P194.	2.5	26
230	Proinflammatory versus anti-inflammatory cytokine profiles as an early predictor of outcome in severe multiple trauma. Critical Care, 2008, 12, P195.	2.5	2
231	Immunoparalysis in patients with acute respiratory distress syndrome. Critical Care, 2008, 12, P196.	2.5	0
232	Transforming growth factor beta 1 gene transcription in infection and severe sepsis displays distinguishing characteristics. Critical Care, 2008, 12, P197.	2.5	0
233	Accumulation of advanced glycation end products in intensive care patients. Critical Care, 2008, 12, P198.	2.5	0
234	Total antioxidant status and lipid metabolism in patients with severe multiple trauma. Critical Care, 2008, 12, P199.	2.5	0
235	Evaluation of plasma thiolic groups and reactive oxygen metabolites in critically ill patients. Critical Care, 2008, 12, P200.	2.5	0
236	Decreased apolipoprotein A1 levels correlate with sepsis and adverse outcome among ICU patients. Critical Care, 2008, 12, P201.	2.5	9
237	Coagulation in hospitalized community-acquired pneumonia: disturbances in even the least ill. Critical Care, 2008, 12, P202.	2.5	2
238	Testing of anti-activated protein C antibodies in four drotrecogin alfa (activated) severe sepsis studies. Critical Care, 2008, 12, P203.	2.5	0

#	Article	IF	CITATIONS
239	Early infusion of recombinant human activated protein C decreases the number of years lost due to premature death. Critical Care, 2008, 12, P204.	2.5	1
240	Extended drotrecogin alfa (activated) therapy in patients with persistent requirement for vasopressor support after 96-hour infusion with commercial drotrecogin alfa (activated). Critical Care, 2008, 12, P205.	2.5	3
241	Drotrecogin alfa: start early, ensure response, stop early!. Critical Care, 2008, 12, P206.	2.5	0
242	Association of mortality in the surgical ICU with plasma concentrations of plasminogen activator inhibitor-1 and soluble E-selectin. Critical Care, 2008, 12, P207.	2.5	0
243	Efficacy of antithrombin administration in the acute phase of burn injury. Critical Care, 2008, 12, P208.	2.5	1
244	Whole blood coagulation and platelet activation in the athlete: a comparison of marathon, triathlon and long-distance running. Critical Care, 2008, 12, P209.	2.5	0
245	Admission platelet count as a prognostic indicator in intensive care. Critical Care, 2008, 12, P210.	2.5	1
246	A phase 1 trial of nebulized heparin in acute lung injury. Critical Care, 2008, 12, P211.	2.5	1
247	Thromboelastography in clinical decision-making in the critically ill patient in a district general hospital ICU. Critical Care, 2008, 12, P212.	2.5	2
248	Modifications of coagulation imbalance during antithrombin treatment in preeclamptic patients: our experience. Critical Care, 2008, 12, P213.	2.5	6
249	Thrombocytopenia is associated with mortality in hospitalized patients with low risk of death. Critical Care, 2008, 12, P214.	2.5	2
250	Functional state of the hemostasis system in physiological pregnancy and late toxicosis. Critical Care, 2008, 12, P215.	2.5	0
251	Plasma fibrinolysis is related to the SOFA score but not to the von Willebrand factor on ICU admission. Critical Care, 2008, 12, P216.	2.5	1
252	Perioperative monitoring of coagulation in patients after abdominal surgery. Critical Care, 2008, 12, P217.	2.5	0
253	Neutrophil oxidative burst evaluation during acute normovolemic hemodilution. Critical Care, 2008, 12, .	2.5	1
254	Reticulocyte counts and their relation to hemoglobin levels in trauma patients. Critical Care, 2008, 12, P219.	2.5	0
255	Geographic variation in the reversal of vitamin K antagonist-associated coagulopathy. Critical Care, 2008, 12, P220.	2.5	0
256	Prothrombin complex concentrate use in surgical patients: a retrospective analysis of efficacy and safety for coumarin reversal and bleeding management. Critical Care, 2008, 12, P221.	2.5	1

~			~
$C1^{-}$	ΓΔΤΙ	ON	Report
$\sim$			KLI OKI

#	Article	IF	CITATIONS
257	Postoperative dose of tranexamic acid decreases postoperative bleeding and inflammatory response associated with cardiopulmonary bypass: a randomized, double-blind study. Critical Care, 2008, 12, P222.	2.5	0
258	Predicting response to recombinant activated factor VIIa administration in the critically ill. Critical Care, 2008, 12, P223.	2.5	0
259	A multicentre prospective open-label study assessing efficacy and safety of a triple-secured fibrinogen concentrate in the treatment of postpartum haemorrhage. Critical Care, 2008, 12, P224.	2.5	1
260	Comparison of prothrombin complex concentrate and fresh frozen plasma on thrombin generation and hemorrhage in experimental dilutional coagulopathy. Critical Care, 2008, 12, P225.	2.5	0
261	Potential effects of infused particles in paediatric intensive care patients. Critical Care, 2008, 12, P226.	2.5	0
262	What is the efficacy of a filter needle in the retention of typical bacterial pathogens?. Critical Care, 2008, 12, P227.	2.5	0
263	Administration of a standardized plasma-protein solution (Biseko®) in high-risk patients with systemic inflammatory response syndrome: influence on cytokine levels and survival. Critical Care, 2008, 12, P228.	2.5	1
264	Albumin versus colloids in colon surgery patients: preliminary results. Critical Care, 2008, 12, P229.	2.5	2
265	Influence of hydroxylethyl starch infusions on cerebral blood flow in patients with severe traumatic brain injury. Critical Care, 2008, 12, P230.	2.5	0
266	Haemodynamic effects of a fluid challenge with hydroxylethyl starch 130/0.4 (Voluven®) in patients suffering from symptomatic vasospasm after subarachnoid haemorrhage. Critical Care, 2008, 12, P231.	2.5	0
267	Hydroxyethyl starch 200/0.5 induces more renal macrophage infiltration than hydroxyethyl starch 130/0.42 in an isolated renal perfusion model. Critical Care, 2008, 12, P232.	2.5	0
268	Hydroxyethyl starch 130/0.42/6:1 for perioperative plasma volume replacement is safe and effective in children. Critical Care, 2008, 12, P233.	2.5	0
269	Effects of two different hydroxyethylstarch solutions on colloid osmotic pressure and renal function in ovine endotoxemic shock. Critical Care, 2008, 12, P234.	2.5	0
270	Transfusion policy and outcome in critically ill patients with a long ICU stay. Critical Care, 2008, 12, P235.	2.5	0
271	Outcome of surgical patients who needed blood transfusion. Critical Care, 2008, 12, .	2.5	0
272	Immediate transfusion without crossmatching. Critical Care, 2008, 12, P237.	2.5	0
273	Intraoperative red blood transfusion is associated with adverse outcome after cardiac surgery. Critical Care, 2008, 12, .	2.5	2
274	Acute transfusion reactions in critically ill pediatric patients. Critical Care, 2008, 12, P239.	2.5	0

		CITATION REPORT	
#	Article	IF	CITATIONS
275	Utility of an artificial oxygen carrier in a rat haemorrhagic shock model. Critical Care, 2008, 12,	P240. 2.5	0
276	Clinical outcome and mortality associated with postoperative low cardiac output after cardiopulmonary bypass: a cohort study. Critical Care, 2008, 12, P241.	2.5	0
277	Renal insufficiency is a powerful predictor of worse outcome in patients with acute heart failure Critical Care, 2008, 12, P242.	2. 2.5	0
278	Study of risk factors and prognoses in female patients younger than 60 years old with acute myocardial infarction. Critical Care, 2008, 12, P243.	2.5	1
279	Impact factors of multiple organ dysfunction syndromes complicating acute myocardial infarcti the elderly: multivariate logistic regression analysis. Critical Care, 2008, 12, P244.	on in 2.5	1
280	Impact factors of pneumonia in hospitalized patients with acute myocardial infarction. Critical (2008, 12, P245.	Care, 2.5	Ο
281	Left ventricular TEI index: comparison between flow and tissue Doppler analyses and its associa with postoperative atrial fibrillation in cardiopulmonary bypass surgery. Critical Care, 2008, 12,		0
282	Color-coded speckle tracking radial strain dyssynchrony analysis in a canine model of left bundle branch block and cardiac resynchronization therapy. Critical Care, 2008, 12, .	e 2.5	Ο
283	Endotoxin impairs the human pacemaker current If. Critical Care, 2008, 12, P248.	2.5	0
284	Cardiac cycle efficiency correlates with pro-B-type natriuretic peptide in cardiac surgery patients Critical Care, 2008, 12, P249.	S. 2.5	3
285	Bradford Acute Coronary Syndrome study $\hat{a} \in $ the impact of primary percutaneous coronary intervention in a tertiary centre: a review of the process. Critical Care, 2008, 12, P250.	2.5	0
286	Preoperative tissue Doppler imaging and diastolic filling patterns on postoperative new-onset a fibrillation in cardiopulmonary bypass surgery. Critical Care, 2008, 12, P251.	trial 2.5	0
287	Risk factors of hospitalisation in general surgery units: new application of International Classification of Diseases. Critical Care, 2008, 12, P252.	2.5	0
288	Prophylactic modalities against venous thromboembolism in complicated surgery for cancer pa Critical Care, 2008, 12, P253.	tients. 2.5	0
289	Cardiac output and oxygen delivery are affected by intraoperative hyperthermic intrathoracic chemotherapy. Critical Care, 2008, 12, P254.	2.5	0
290	Influence of donor gender in early outcome after lung transplantation. Critical Care, 2008, 12, F	P255. 2.5	Ο
291	Early outcome following single versus bilateral lung transplantation in recipients 60 years of aga and older. Critical Care, 2008, 12, P256.	e 2.5	1
292	Acute mesenteric ischemia: a comparative study of causes and mortality rates in Shiraz, Southe Critical Care, 2008, 12, P257.	rn Iran. 2.5	0

#	Article	IF	CITATIONS
293	Systemic inflammatory response syndrome post cardiac surgery: a useful concept?. Critical Care, 2008, 12, P258.	2.5	2
294	Modulation of the inflammatory response induced during coronary artery bypass graft surgery. Critical Care, 2008, 12, P259.	2.5	0
295	Intraoperative optimization of hemodynamic parameters is associated with a better outcome after cardiac surgery. Critical Care, 2008, 12, .	2.5	0
296	Effects of inhaled iloprost on right ventriculovascular coupling and ventricular interdependence in acute pulmonary hypertension. Critical Care, 2008, 12, P261.	2.5	Ο
297	Dobutamine in acute myocardial infarction: should we use it for reduction of pulmonary hypertension and pulmonary capillary wedge pressure in acute myocardial infarction?. Critical Care, 2008, 12, P262.	2.5	0
298	Dobutamine protects lymphocytes against staurosporin-induced apoptosis: investigation of the antioxidative action of the dobutamine molecule. Critical Care, 2008, 12, P263.	2.5	0
299	Hemodynamic effects of levosimendan in patients with low-output heart failure. Critical Care, 2008, 12, P264.	2.5	0
300	Levosimendan does not improve resuscitation success after hypovolemic cardiac arrest. Critical Care, 2008, 12, P265.	2.5	1
301	Early experience with levosimendan in children with low-output syndrome after cardiac surgery. Critical Care, 2008, 12, .	2.5	0
302	Effects of levosimendan in acute heart failure, cardiogenic and septic shock. Critical Care, 2008, 12, P267.	2.5	Ο
303	Sedation during mechanical ventilation: a comparison of sedatonarcosis and awake sedation. Critical Care, 2008, 12, P268.	2.5	0
304	Multiparametric evaluation of sedation in the ICU. Critical Care, 2008, 12, P269.	2.5	1
305	Short-term sevoflurane sedation using the anaesthetic conserving device AnaConDa® after cardiac surgery: feasibility, recovery and clinical issues. Critical Care, 2008, 12, P270.	2.5	2
306	Thoracal epidural analgesia in upper abdominal surgery. Critical Care, 2008, 12, P271.	2.5	1
307	Etomidate and relative adrenal insufficiency in cardiopulmonary bypass surgery: impact on the postoperative hemodynamic status. Critical Care, 2008, 12, P272.	2.5	0
308	Economic evaluation of remifentanil-based versus conventional sedation for patients with an anticipated mechanical ventilation duration of 2–3 days in Germany. Critical Care, 2008, 12, P273.	2.5	Ο
309	Propofol pharmacokinetics in preterm and term neonates: the relevance of both postmenstrual and postnatal age. Critical Care, 2008, 12, P274.	2.5	1
310	Comparison of sedation with dexmedetomidine versus lorazepam in septic ICU patients. Critical Care, 2008, 12, P275.	2.5	16

#	Article	IF	CITATIONS
311	Dexmedetomidine-based sedation for noninvasive ventilation failure. Critical Care, 2008, 12, P276.	2.5	0
312	Dexmedetomidine for endovascular neurosurgery. Critical Care, 2008, 12, P277.	2.5	0
313	Single-centre audit on the use of intravenous paracetamol in neonates. Critical Care, 2008, 12, P278.	2.5	0
314	Postmenstrual age and CYP2D6 polymorphisms determine urinary tramadol O-demethylation excretion in critically ill neonates and infants. Critical Care, 2008, 12, P279.	2.5	1
315	Pressure support ventilation improves oxygenation by redistribution of pulmonary blood flow in experimental lung injury. Critical Care, 2008, 12, P280.	2.5	0
316	Model based analysis reveals differences in viscoelasticity between acute respiratory distress syndrome and healthy lungs. Critical Care, 2008, 12, P281.	2.5	0
317	Short time efficacy and safety of modified pressure-controlled ventilation recruitment maneuver in a group of patients with acute respiratory distress syndrome. Critical Care, 2008, 12, P282.	2.5	1
318	Effect of frequency on lung protection during high-frequency oscillation ventilation in a sheep acute respiratory distress syndrome model. Critical Care, 2008, 12, P283.	2.5	0
319	Hungarian sites of the multinational VALID study are responsive to training measures advocating the ARDS Network ventilation protocol. Critical Care, 2008, 12, P284.	2.5	0
320	High-frequency oscillatory ventilation and adult patients with acute respiratory distress syndrome: our impressions and experience. Critical Care, 2008, 12, P285.	2.5	1
321	Perfusion pressure and positive end-expiratory pressure influence edema formation in isolated porcine lungs. Critical Care, 2008, 12, P286.	2.5	0
322	Closed system endotracheal suction to reduce loss in functional residual capacity during pressure-controlled mechanical ventilation. Critical Care, 2008, 12, P287.	2.5	0
323	Effects of melatonin in an experimental model of ventilator-induced lung injury. Critical Care, 2008, 12, P288.	2.5	1
324	Hyperoxia inhibits alveolar epithelial repair by inhibiting the transdifferentiation of alveolar epithelial type II cells into type I cells. Critical Care, 2008, 12, P289.	2.5	1
325	Pretreatment with atorvastatin ameliorates lung injury caused by high-pressure/high-tidal-volume mechanical ventilation in isolated normal rabbit lungs. Critical Care, 2008, 12, P290.	2.5	0
326	Systemic markers of inflammation in mechanically ventilated brain-injured patients in the absence of sepsis and acute lung injury: the effect of positive end-expiratory pressure. Critical Care, 2008, 12, P291.	2.5	0
327	Shotgun proteomics reveals biochemistry of normal and acute respiratory distress syndrome bronchoalveolar lavage fluid proteome. Critical Care, 2008, 12, P292.	2.5	0
328	Surrogate markers of pulmonary edema and severity of lung injury do not accurately reflect measured extravascular lung water. Critical Care, 2008, 12, P293.	2.5	0

#	Article	IF	CITATIONS
329	Different tidal volumes induce similar elevation of lung injury markers in animals sensitized to injury by previous anesthesia and surgery. Critical Care, 2008, 12, P294.	2.5	0
330	Effects of an open lung approach following the ARDS Network ventilatory strategy in patients with early acute lung injury/acute respiratory distress syndrome. Critical Care, 2008, 12, P295.	2.5	0
331	From low-tidal-volume ventilation to lowest-tidal-volume ventilation. Critical Care, 2008, 12, P296.	2.5	0
332	Relationship of the stress index, lung recruitment and gas exchange in patients with acute respiratory distress syndrome. Critical Care, 2008, 12, P297.	2.5	1
333	Pulmonary homogenicity changes during recruitment maneuvers and positive end-expiratory pressure in dogs with acute respiratory distress syndrome. Critical Care, 2008, 12, P298.	2.5	0
334	Positive end-expiratory pressure-induced changes of the vibration response image. Critical Care, 2008, 12, P299.	2.5	1
335	Effect of positive end-expiratory pressure application on inflammation in acute respiratory distress syndrome patients during pressure–volume curve maneuver. Critical Care, 2008, 12, P300.	2.5	0
336	Airway pressure release ventilation: an alternative ventilation mode for pediatric acute respiratory distress syndrome. Critical Care, 2008, 12, P301.	2.5	0
337	Influence of rhDNAse on the duration of mechanical ventilation in intensive care patients. Critical Care, 2008, 12, P302.	2.5	0
338	Respiratory dialysis: a new therapy for chronic obstructive pulmonary disease. Critical Care, 2008, 12, P303.	2.5	0
339	Effect of the inspiratory flow pattern on inspiration/expiration transition of lung vibrations in mechanically ventilated patients. Critical Care, 2008, 12, P304.	2.5	0
340	Effect of the pressure ramp on the breathing pattern and respiratory drive in pressure support ventilation. Critical Care, 2008, 12, P305.	2.5	0
341	Knowledge acquisition to design a fuzzy system for disease-specific automatic control of mechanical ventilation. Critical Care, 2008, 12, P306.	2.5	0
342	Use of chest sonography to estimate alveolar recruitment in general anesthesia. Critical Care, 2008, 12, P307.	2.5	0
343	Lung sound analysis to detect recruitment processes during mechanical ventilation. Critical Care, 2008, 12, P308.	2.5	2
344	Lung sound patterns of exacerbation of congestive heart failure, chronic obstructive pulmonary disease and asthma. Critical Care, 2008, 12, P309.	2.5	0
345	Determination of expiratory lung mechanics using cardiogenic oscillations during decelerated expiration. Critical Care, 2008, 12, P310.	2.5	0
346	Cardiogenic oscillations reflect nonlinear lung mechanics. Critical Care, 2008, 12, P311.	2.5	Ο

#	Article	IF	CITATIONS
347	Functional residual capacity measurements during mechanical ventilation in ICU patients. Critical Care, 2008, 12, P312.	2.5	1
348	Clinical evaluation of a system for measuring functional residual capacity in mechanically ventilated patients. Critical Care, 2008, 12, P313.	2.5	0
349	Effects of alveolar recruitment in patients after cardiac surgery: a prospective, randomized, controlled clinical trial. Critical Care, 2008, 12, P314.	2.5	1
350	Evaluation of homogeneity of alveolar ventilation with electrical impedance tomography during anaesthesia and laparoscopic surgery. Critical Care, 2008, 12, P315.	2.5	0
351	Serum level of growth-related oncogene alpha during abdominal aortic aneurysm repair in humans. Critical Care, 2008, 12, P316.	2.5	1
352	Serum bilirubin over 50 μmol/l on postoperative day 5: causes, consequences and outcome. Critical Care, 2008, 12, P317.	2.5	1
353	Liver stiffness measurement for diagnosis of portal hypertension-related digestive bleeding in the ICU. Critical Care, 2008, 12, P318.	2.5	0
354	Small intestinal transit time in critically ill patients using endoscopic video capsule. Critical Care, 2008, 12, P319.	2.5	1
355	Transpulmonary pressure evaluation in an obese patient under mechanical ventilation. Critical Care, 2008, 12, P320.	2.5	0
356	Passive mechanical properties of rat diaphragms: a new method for analyzing mechanical tissue properties. Critical Care, 2008, 12, P321.	2.5	0
357	Negative pressure therapy improved outcome in a clinically applicable abdominal compartment syndrome porcine model. Critical Care, 2008, 12, P322.	2.5	0
358	Clinically applicable porcine model of abdominal compartment syndrome. Critical Care, 2008, 12, P323.	2.5	0
359	Relation between ventilatory pressures and intra-abdominal pressure. Critical Care, 2008, 12, P324.	2.5	4
360	Evaluation of the role of noninvasive positive pressure ventilation in prevention of postextubation respiratory failure in high-risk patients. Critical Care, 2008, 12, P325.	2.5	0
361	A randomized control trial comparing adaptive support ventilation with pressure-regulated volume control ventilation in weaning patients after cardiac surgery. Critical Care, 2008, 12, P326.	2.5	1
362	Effectiveness of a spontaneous breathing trial with a low-pressure support protocol for liberation from the mechanical ventilator in a general surgical ICU. Critical Care, 2008, 12, P327.	2.5	0
363	Predicting success in weaning from mechanical ventilation. Critical Care, 2008, 12, P328.	2.5	2
364	Is the threshold useful in accelerating weaning from mechanical ventilation?. Critical Care, 2008, 12, P329.	2.5	1

#	Article	IF	CITATIONS
365	Addition of a spontaneous awakening trial improves outcome in mechanically ventilated medical ICU patients. Critical Care, 2008, 12, P330.	2.5	0
366	Early versus late tracheotomy in the ICU. Critical Care, 2008, 12, P331.	2.5	1
367	Precocious tracheotomy versus prolonged intubation in a medical ICU. Critical Care, 2008, 12, P332.	2.5	0
368	Ciaglia Blue Dolphin: a new technique for percutaneous tracheostomy using balloon dilation. Critical Care, 2008, 12, P333.	2.5	3
369	Percutaneous dilatation tracheostomy in critically ill patients with documented coagulopathy. Critical Care, 2008, 12, P334.	2.5	0
370	An audit of perioperative staffing and complications during percutaneous and surgical tracheostomy insertion. Critical Care, 2008, 12, P335.	2.5	0
371	Severe airway compromise after percutaneous dilatational tracheostomy. Critical Care, 2008, 12, P336.	2.5	0
372	Incidence of postoperative sore throat and cough: comparison of a polyvinylchloride tube and an armoured tube. Critical Care, 2008, 12, P337.	2.5	1
373	Efficacy of postprocedural chest radiographs after percutaneous dilational tracheostomy. Critical Care, 2008, 12, P338.	2.5	0
374	Tracheal wall pressures in the clinical setting: comparing Portex Soft Seal and Lotrach cuffs. Critical Care, 2008, 12, P339.	2.5	0
375	Intraluminal measurement probe increases resistance of pediatric endotracheal tubes. Critical Care, 2008, 12, P340.	2.5	0
376	Effect of telemedicine for a prehospital suburban emergency medical service. Critical Care, 2008, 12, P341.	2.5	3
377	An improved Bussignac device for the delivery of noninvasive continuous positive airway pressure: the SUPER-Bussignac. Critical Care, 2008, 12, P342.	2.5	0
379	How quick is soon? Early response to continuous positive airway pressure: a randomized controlled trial. Critical Care, 2008, 12, P344.	2.5	1
380	Conventional versus noninvasive ventilation in acute respiratory failure. Critical Care, 2008, 12, P345.	2.5	0
381	Can the delta Rapid Shallow Breathing Index predict respiratory failure in spontaneously breathing patients receiving positive pressure ventilation?. Critical Care, 2008, 12, P346.	2.5	0
382	Plain radiological investigations in admissions to a trauma centre ICU. Critical Care, 2008, 12, P347.	2.5	0
383	Needlestick injuries and infectious diseases in emergency medicine. Critical Care, 2008, 12, P348.	2.5	Ο

		CITATION RE	EPORT	
#	Article		IF	CITATIONS
384	Impact of a pandemic triage tool on intensive care admission. Critical Care, 2008, 12, I	>349.	2.5	2
385	Pneumonia Severity Index: a validation and assessment study for its use as a triage too emergency department. Critical Care, 2008, 12, P350.	bl in the	2.5	0
386	Injuries sustained by patients with behavioral disturbances brought to an emergency d police custody. Critical Care, 2008, 12, P351.	epartment in	2.5	0
387	A study on the reliability and validity of two four-level emergency triage systems. Critic 12, P352.	al Care, 2008,	2.5	Ο
388	Patterns of medical illness and injuries in emotionally disturbed patients brought to an department in police custody. Critical Care, 2008, 12, P353.	emergency	2.5	0
389	Factors of hospitalization for mild heat illness. Critical Care, 2008, 12, P354.		2.5	Ο
390	Missed opportunities to facilitate the diagnosis of colon cancer in emergency departm Critical Care, 2008, 12, P355.	ent patients.	2.5	4
391	When are chest X-ray scans performed in the emergency department useful?. Critical ( P356.	Care, 2008, 12,	2.5	Ο
392	Management of acute organophosphorus poisoning at a university hospital. Critical Ca P357.	are, 2008, 12,	2.5	0
393	Suicidal intoxication by the black stone in Tunisia. Critical Care, 2008, 12, P358.		2.5	Ο
394	Prognosis factors of poisonings treated with extracorporeal life support in the ICU. Cri 2008, 12, P359.	tical Care,	2.5	1
395	Prognostic factors of acute calcium-channel blocker poisonings. Critical Care, 2008, 12	2, P360.	2.5	Ο
396	Retrospective study of patients following deliberate self-poisoning admitted to Cardiff critical care services between April 2006 and December 2007. Critical Care, 2008, 12,		2.5	0
397	Immunological manifestations in paraphenylenediamine poisoning. Critical Care, 2008	, 12, P362.	2.5	0
398	Introducing rapid response teams in Slovenia. Critical Care, 2008, 12, P363.		2.5	1
399	Emergency call system in the hospital. Critical Care, 2008, 12, P364.		2.5	Ο
400	Relevance of a cardiac arrest team in an Indian cancer hospital ICU. Critical Care, 2008	, 12, P365.	2.5	0
401	Outcome after ICU admission following out-of-hospital cardiac arrest in a UK teaching Critical Care, 2008, 12, P366.	hospital.	2.5	1

#	Article	IF	CITATIONS
402	Comparison of the characteristics and outcome between patients suffering from out-of-hospital primary cardiac arrest and drowning victims with cardiac arrest: an analysis of variables based on the Utstein Style for Drowning. Critical Care, 2008, 12, P367.	2.5	0
403	Trends (1998–2006) in hospital mortality for admissions to UK critical care units following cardiopulmonary resuscitation. Critical Care, 2008, 12, P368.	2.5	0
404	Return of spontaneous circulation after cardiac arrest using mechanical chest compressions with the Lund Cardiac Arrest System compared with manual chest compressions. Critical Care, 2008, 12, P369.	2.5	0
406	Return of spontaneous circulation and neurological outcome after inhospital Lund University Cardiac Arrest System cardiopulmonary resuscitation. Critical Care, 2008, 12, P371.	2.5	0
407	Etiology of prehospital cardiac arrest largely determines outcome in patients treated with mild hypothermia. Critical Care, 2008, 12, P372.	2.5	0
408	Good neurological recovery at ICU discharge of asystole patients treated with induced mild hypothermia. Critical Care, 2008, 12, P373.	2.5	2
409	Use of hypothermia for out-of-hospital cardiac arrest survivors: a single-centre experience. Critical Care, 2008, 12, P374.	2.5	0
410	Therapeutic hypothermia preserves the brain by reducing nitric oxide synthase after asphyxial cardiac arrest in rats. Critical Care, 2008, 12, P375.	2.5	1
411	Cerebral blood flow and cerebrovascular reactivity during hypothermia after cardiac arrest. Critical Care, 2008, 12, P376.	2.5	0
412	Early therapeutic hypothermia in sudden cardiac death and following return of spontaneous circulation. Critical Care, 2008, 12, P377.	2.5	0
413	Effect of therapeutic mild hypothermia initiated by cold fluids after cardiac arrest on haemostasis as measured by thrombelastography. Critical Care, 2008, 12, P378.	2.5	0
414	Immunomodulatory effects of esmolol in a septic animal model due to multidrug-resistant Pseudomonas aeruginosa pyelonephritis. Critical Care, 2008, 12, P379.	2.5	2
415	Applying the 2003 SCCM/ESICM/ACCP/ATS/SIS instead of the 1992 ACCP/SCCM sepsis definitions increases the numbers of patients with systemic inflammatory response syndrome shock and septic shock but decreases mortality rates. Critical Care, 2008, 12, P380.	2.5	0
416	Systemic inflammatory response syndrome as a clinical detection tool and inclusion criterion in sepsis trials: too blunt an instrument?. Critical Care, 2008, 12, P381.	2.5	0
417	Pharmacokinetic–pharmacodynamic analysis of human purified C1-esterase inhibitor in patients with sepsis. Critical Care, 2008, 12, P382.	2.5	1
418	Nitrite consumption and production in the cardiopulmonary circulation during hemorrhagic shock and resuscitation. Critical Care, 2008, 12, P383.	2.5	0
419	Postconditioning in a rat model of gut ischemia-reperfusion. Critical Care, 2008, 12, P384.	2.5	0
420	Endotoxin-induced activation of hypoxia-inducible factor 1α in cultured human hepatocytes and monocytes: impact on cellular and mitochondrial respiration. Critical Care, 2008, 12, P385.	2.5	Ο

#	Article	IF	CITATIONS
421	Induction of hypoxia inducible factor 1α by Toll-like receptors in human dendritic cells. Critical Care, 2008, 12, P386.	2.5	1
422	Association between ATP production and oxidative mtDNA damage through mitochondrial respiratory chain in the rat caecal ligation and puncture heart injury model. Critical Care, 2008, 12, P387.	2.5	0
423	Cecal ligation and perforation, when disrupting proper abscess formation, provides highly reproducible results and has common features with human data. Critical Care, 2008, 12, P388.	2.5	0
424	Hydrogen sulfide for organ protection. Critical Care, 2008, 12, P389.	2.5	Ο
425	Experimental wound healing in severe sepsis and septic shock in humans. Critical Care, 2008, 12, P390.	2.5	1
426	Effect of increasing endotoxin doses on oxidative injury and cyclooxygenase-mediated inflammation in the anaesthetised pig. Critical Care, 2008, 12, P391.	2.5	0
427	Nitric oxide synthase 2-derived NO in endotoxemia is not sufficient to cause hemodynamic effects. Critical Care, 2008, 12, P392.	2.5	0
428	Lipopolysaccharide modulation of phenylephrine-dependent vasoconstriction is dependent on intercellular communication. Critical Care, 2008, 12, P393.	2.5	0
429	Effects of inhaled carbon monoxide and glucocorticoids in porcine endotoxin sepsis. Critical Care, 2008, 12, P394.	2.5	3
430	Endotoxemia induces an early differential metabolic response in the heart and liver as determined by metabolomic analysis. Critical Care, 2008, 12, P395.	2.5	0
431	Noradrenaline for treatment of endotoxemic shock in pigs is associated with improved hepatic mitochondrial respiration. Critical Care, 2008, 12, P396.	2.5	0
432	Central-line-related septic shock: early appropriate antimicrobial therapy and rapid source control reduce mortality. Critical Care, 2008, 12, P397.	2.5	0
433	Optimal hemodynamic management according to the Surviving Sepsis Guidelines is not applicable to all ICU patients. Critical Care, 2008, 12, P398.	2.5	3
434	Outcome and mortality risk factors of patients presenting to the ICU with severe sepsis and septic shock. Critical Care, 2008, 12, P399.	2.5	0
435	Evaluation of indications for performing blood cultures in ICU patients: a pilot study. Critical Care, 2008, 12, P400.	2.5	0
436	Meta-analysis of dopexamine and its effect on mortality in patients undergoing major surgery. Critical Care, 2008, 12, P401.	2.5	0
437	Glucose metabolism during hyperdynamic septic shock: comparison between noradrenaline and vasopressin. Critical Care, 2008, 12, P402.	2.5	1
438	Continuous terlipressin versus vasopressin infusion in septic shock: the TERLIVAP study. Critical Care, 2008, 12, P403.	2.5	6

#	Article	IF	CITATIONS
439	Hemodynamic effects of association of vasopressin and norepinephrine in patients with septic shock. Critical Care, 2008, 12, P404.	2.5	1
440	Vasopressin and terlipressin as first-line therapy in fulminant ovine septic shock. Critical Care, 2008, 12, P405.	2.5	3
441	Terlipressin in catecholamine-resistant hyperdynamic shock patients after cardiac surgery. Critical Care, 2008, 12, .	2.5	1
442	Selective V1a receptor agonist FE 202158 reverses platelet-activating factor-induced hypotension, vascular leak, impaired tissue perfusion, and mortality in rats. Critical Care, 2008, 12, P407.	2.5	9
443	Comparison of vasoactive medications and investigation determinants of mortality in children. Critical Care, 2008, 12, P408.	2.5	0
444	Importance of adequate fluid resuscitation in patients with severe septic shock on high catecholamine doses. Critical Care, 2008, 12, P409.	2.5	1
445	Low cardiac function index predicts ICU mortality in patients with severe sepsis or septic shock. Critical Care, 2008, 12, P410.	2.5	2
446	Australasian Resuscitation in Sepsis Evaluation study. Critical Care, 2008, 12, P411.	2.5	0
447	Survival sepsis campaign bundles, compliance and mortality: prospective single-center study. Critical Care, 2008, 12, P412.	2.5	0
448	Compliance of Surviving Sepsis Campaign bundles: single-center perspective of 3 years. Critical Care, 2008, 12, P413.	2.5	0
449	Compliance with the sepsis care resuscitation bundles is associated with decreased mortality in patients with septic shock. Critical Care, 2008, 12, P414.	2.5	0
450	Severe sepsis: international and specialty variations in initial management. Critical Care, 2008, 12, P415.	2.5	2
451	Surviving sepsis in Scotland: is the emergency department ready?. Critical Care, 2008, 12, P416.	2.5	0
452	A multicentre study on early goal-directed therapy of severe sepsis and septic shock patients in the ICU: collaborative study group on early goal-directed therapy in Zhejiang Province, China. Critical Care, 2008, 12, P417.	2.5	2
453	Effect of prolonged emergency department length of stay on inpatient length of stay and inhospital mortality in severe sepsis and septic shock. Critical Care, 2008, 12, P418.	2.5	0
454	Does early antibiotic administration affect disposition or length of stay in patients with cryptic shock? A retrospective pilot study. Critical Care, 2008, 12, P419.	2.5	0
455	Location of presentation of septic shock has an impact on clinical outcome. Critical Care, 2008, 12, P420.	2.5	0
456	Effects of hydrocortisone on posttraumatic stress disorder after septic shock: results from the CORTICUS Berlin Study Group. Critical Care, 2008, 12, P421.	2.5	4

		CITATION REPORT	
#	Article	IF	CITATIONS
457	Possible pharmacologic interactions caused by mixed infusion. Critical Care, 2008, 12, P422.	2.5	0
458	Influence of the number of nurses on survival in multiple system organ failure. Critical Care, 2008, P423.	12, 2.5	0
459	Racial disparities in quality of care in community-acquired pneumonia. Critical Care, 2008, 12, P42	4. 2.5	0
460	Global assessment of performance of ICUs: a French experience. Critical Care, 2008, 12, P425.	2.5	0
461	AlMing to save lives. Critical Care, 2008, 12, P426.	2.5	2
462	Standard operating procedures in postresuscitation care: facilitated realisation therapeutic measurin daily practice. Critical Care, 2008, 12, P427.	res 2.5	0
463	Artificial intelligence to reduce practice variation in the ICU. Critical Care, 2008, 12, P428.	2.5	0
464	Design, implementation and evaluation of a new drug chart in an intensive care/high-dependency ι Critical Care, 2008, 12, P429.	unit. 2.5	0
465	Northern Ireland Critical Care Incident Monitoring Study. Critical Care, 2008, 12, P430.	2.5	0
466	Four-dimensional approach to quality and performance of intensive care: rapid routine overview of performance by derived indexes. Critical Care, 2008, 12, P431.	2.5	0
467	Quality improvement: reducing ventilator-associated pneumonia. Critical Care, 2008, 12, P432.	2.5	1
468	Ventilator-associated pneumonia bundle impact in an intermediate respiratory care unit. Critical Ca 2008, 12, P433.	are, 2.5	0
469	Implementing national guidelines in intensive care patients with ventilator-associated, hospital-acquired, and healthcare-associated pneumonia: the IMPACT-HAP project. Critical Care, 20 12, P434.	008, 2.5	0
470	Prevention of unplanned extubations in the ICU: results of a nurse-driven endotracheal tube care protocol. Critical Care, 2008, 12, P435.	2.5	0
471	Evidence-based guidelines for preventing ventilator-associated pneumonia: results of a knowledge test among 3329 European intensive care nurses. Critical Care, 2008, 12, P436.	2.5	0
472	Preliminary investigation into the response of free cortisol to the low-dose corticotrophin test in patients with septic shock. Critical Care, 2008, 12, P437.	2.5	0
473	Copeptin as a marker of shock and predictor of adverse outcome in critically ill patients. Critical Care, 2008, 12, P438.	2.5	1
474	Copeptin and acute renal failure in critically ill patients. Critical Care, 2008, 12, P439.	2.5	3

			2
#	ARTICLE	IF	CITATIONS
475	Prognostic value of N-terminal B-type natriuretic peptide in patients at high risk of systemic inflammatory response syndrome/sepsis. Critical Care, 2008, 12, P440.	2.5	0
476	Incremental power of the combination of brain natriuretic peptide and tumoral antigen carbohydrate 125 for risk stratification in patients with acute heart failure. Critical Care, 2008, 12, P441.	2.5	0
477	Pro-brain natriuretic peptide as a marker of successful thrombolysis in patients with submassive pulmonary thromboembolism. Critical Care, 2008, 12, P442.	2.5	0
478	Serum measurement of N-terminal pro-brain peptide among septic patients. Critical Care, 2008, 12, P443.	2.5	0
479	Plasma brain natriuretic peptide and cardiac troponin I concentrations after adult cardiac surgery: association with cardiovascular death, postoperative cardiac, renal and pulmonary dysfunction. Critical Care, 2008, 12, .	2.5	0
480	Prognostic value of plasma amino-terminal pro-brain natriuretic peptide in a large, representative ICU population. Critical Care, 2008, 12, P445.	2.5	0
481	N-terminal B-type natriuretic peptide and renal function parameters in cerebral salt wasting syndrome. Critical Care, 2008, 12, P446.	2.5	0
482	Sepsis-associated diastolic dysfunction without elevated plasma B-type natriuretic peptide. Critical Care, 2008, 12, P447.	2.5	0
483	Effects of postoperative hyperlactatemia on patients' intensive therapy unit length of stay. Critical Care, 2008, 12, P449.	2.5	0
484	Intraoperative base excess and carbon dioxide gap predict length of intensive care stay after cardiac surgery. Critical Care, 2008, 12, P450.	2.5	0
485	Lactate clearance: the earlier the better?. Critical Care, 2008, 12, P451.	2.5	0
486	Interpretation of serum lactate levels in septic hyperlactatemic patients with acute respiratory distress syndrome. Critical Care, 2008, 12, P452.	2.5	0
487	Intravenous immunoglobulin reduces the ischemia/reperfusion-induced renal injury by increasing insulin-like growth factor-I production in mice. Critical Care, 2008, 12, P453.	2.5	0
488	Comparative study between intravenous immunoglobulins and standard treatment in septic patients. Critical Care, 2008, 12, P454.	2.5	1
489	Lipopolysaccharide adsorption in combined therapy of patients with severe sepsis. Critical Care, 2008, 12, P455.	2.5	4
490	Relationship between the use of polymyxin B-immobilized fiber for hemofiltration and some laboratory parameters (endocannabinoids, high mobility group box-1 protein and oxidative stress) in severe pneumonia patients. Critical Care, 2008, 12, P456.	2.5	0
491	Effectiveness of continuous venovenous hemodiafiltration using a polymethylmethacrylate membrane hemofilter in septic shock patients. Critical Care, 2008, 12, P457.	2.5	0
492	Polymyxin B hemoperfusion in high endotoxin activity level septic shock patients. Critical Care, 2008, 12, P458.	2.5	3

	Сітатіо	n Report	
#	Article	IF	Citations
493	Efficacy of the CTR-001 direct hemoperfusion adsorption column in sepsis. Critical Care, 2008, 12, P459.	2.5	0
494	Coupled plasma filtration adsorption in peritonitis-induced porcine hyperdynamic septic shock. Critical Care, 2008, 12, P460.	2.5	1
495	Clinical efficacy of long-term performance with polymyxin-B immobilized fiber treatment for septic shock. Critical Care, 2008, 12, P461.	2.5	0
496	Association of IL-6 promoter polymorphism -174C/G with outcome in severe sepsis. Critical Care, 2008, 12, P462.	2.5	4
497	Association of (CCTTT)10, a nitric oxide synthase 2 promoter polymorphism, with death due to acute lung injury. Critical Care, 2008, 12, P463.	2.5	0
498	Tranexamic acid effects on postoperative bleeding in cardiopulmonary bypass surgery according to the plasminogen activator inhibitor-1 polymorphism. Critical Care, 2008, 12, P464.	2.5	0
499	Effect of the IL-6 promoter polymorphism -174 G/C on risk and outcome of pneumonia. Critical Care, 2008, 12, P465.	2.5	4
500	Relationship between angiotensin-converting enzyme gene polymorphism (insertion/deletion) and the clinical condition of sepsis. Critical Care, 2008, 12, P466.	2.5	0
501	Incidence of renal failure following orthotopic liver transplantation is lower in the Asian population. Critical Care, 2008, 12, P467.	2.5	0
502	Renal protection in the ICU: role of fenoldopam. Critical Care, 2008, 12, P468.	2.5	0
503	Renal hemodynamic, microcirculatory and metabolic responses to peritonitis-induced acute kidney injury in pigs. Critical Care, 2008, 12, P469.	2.5	3
504	Risk factors and outcome of rhabdomyolysis after cardiac surgery. Critical Care, 2008, 12, .	2.5	4
505	Requirement for renal replacement therapy following orthotopic liver transplantation in adults is associated with prolonged mechanical ventilation and higher incidence of pneumonia. Critical Care, 2008, 12, P471.	2.5	0
506	Slow continuous ultrafiltration: just fluids?. Critical Care, 2008, 12, P472.	2.5	0
507	New technology for mini invasive slow continuous ultrafiltration to avoid mechanical ventilation in cardiorespiratory failure: preliminary experience. Critical Care, 2008, 12, P473.	2.5	0
508	Provision of intermittent renal replacement service outside an ICU is safe and effective. Critical Care, 2008, 12, P474.	2.5	0
509	The Hannover Dialysis Outcome (HAN-D-OUT) study: comparison of standard versus intensified dialysis in treatment of patients with acute kidney injury in the ICU. Critical Care, 2008, 12, P475.	2.5	2
510	High-volume continuous venovenous hemofiltration reduces mortality in critically ill patients with acute renal failure. Critical Care, 2008, 12, P476.	2.5	0

#	Article	IF	CITATIONS
511	High fluid volume removal with continuous renal replacement therapy as a therapeutic option for early posttraumatic acute respiratory distress syndrome. Critical Care, 2008, 12, P477.	2.5	0
512	Serum urea as a marker for initiation of renal replacement therapy in ICU patients with acute kidney injury. Critical Care, 2008, 12, P478.	2.5	3
513	Initiation of renal replacement therapy in patients with acute kidney injury and severe lactic acidosis. Critical Care, 2008, 12, P479.	2.5	1
514	Pharmacokinetics of ranitidine during hemodiafiltration. Critical Care, 2008, 12, P480.	2.5	0
515	Ceftriaxone pharmacokinetic properties during continuous venovenous haemofiltration using an in vitro model. Critical Care, 2008, 12, P481.	2.5	1
516	Intermittent versus continuous enoxaparine for anticoagulation during continuous venovenous hemofiltration. Critical Care, 2008, 12, P482.	2.5	0
517	Mechanical ventilation in a critical care unit in southern Brazil: mortality risk factors. Critical Care, 2008, 12, P483.	2.5	1
518	Long-stay critically ill patients' characteristics and outcomes: a cohort study. Critical Care, 2008, 12, P484.	2.5	1
519	Respiratory organ dysfunction: a leading risk factor for hospital mortality in patients with severe sepsis or septic shock. Critical Care, 2008, 12, P485.	2.5	0
520	Improved ICU risk prediction modelling using a multivariable fractional polynomial approach. Critical Care, 2008, 12, P486.	2.5	0
521	Risk factors for the development of acute lung injury in patients with septic shock: an observational cohort study. Critical Care, 2008, 12, P487.	2.5	21
522	Outcome in severe sepsis and septic shock patients with hematological malignancies: impact of recent intravenous chemotherapeutic treatment. Critical Care, 2008, 12, P488.	2.5	0
523	Outcome of patients with haematological malignancy admitted to the general ICU. Critical Care, 2008, 12, P489.	2.5	0
524	Prognostic factors of cancer patients admitted to the ICU in Brazil: a prospective cohort. Critical Care, 2008, 12, P490.	2.5	0
525	Organ dysfunction influences outcome in medical oncology patients without multiorgan failure. Critical Care, 2008, 12, P491.	2.5	0
526	Causes and risk factors of maternal mortality in the ICU. Critical Care, 2008, 12, P492.	2.5	2
527	Epidemiology and outcome in acute respiratory failure. Critical Care, 2008, 12, P493.	2.5	2
528	Outcome for immunocompromised pediatric critical patients. Critical Care, 2008, 12, P494.	2.5	0

#	Article	IF	CITATIONS
529	Immunocompromised pediatric patients with acute respiratory failure: outcome and prognosis factors. Critical Care, 2008, 12, P495.	2.5	0
530	ICU patients: does age make any difference?. Critical Care, 2008, 12, P496.	2.5	1
531	How does care differ for neurological patients admitted to a neuro-ICU versus a general ICU? The Greater New York Hospital Association ICU Prevalence Survey. Critical Care, 2008, 12, P497.	2.5	0
532	Analysis of morbimortality in patients with multiorgan dysfunction. Critical Care, 2008, 12, P498.	2.5	1
533	Determination of SpO2/FiO2 thresholds to impute for PaO2/FiO2 ratios in the Sequential Organ Failure Assessment score. Critical Care, 2008, 12, P499.	2.5	0
534	Validation of APACHE IV in patients with severe acute pancreatitis. Critical Care, 2008, 12, P500.	2.5	1
535	Disparity in outcome prediction between APACHE II, APACHE III and APACHE IV. Critical Care, 2008, 12, P501.	2.5	3
536	Assessment of the performance of the SAPS 3, SAPS II, and APACHE II prognostic models in a surgical ICU. Critical Care, 2008, 12, P502.	2.5	1
537	Prediction of hospital mortality by support vector machine versus logistic regression in patients with a haematological malignancy admitted to the ICU. Critical Care, 2008, 12, P503.	2.5	1
538	Incidence, risk factors and outcome of venous thromboembolism in critically ill obstetric patients. Critical Care, 2008, 12, P504.	2.5	0
539	Quality of life after prolonged ICU stay: preliminary results of a prospective survey in critically ill patients. Critical Care, 2008, 12, P505.	2.5	0
541	Quality of life 4 months after ICU discharge. Critical Care, 2008, 12, P507.	2.5	0
542	Quality of life among survivors of prolonged critical illness; a mixed methods study. Critical Care, 2008, 12, P508.	2.5	0
543	Long-term resource use, quality of life, and cost-effectiveness of liberal and conservative fluid strategies in acute lung injury. Critical Care, 2008, 12, P509.	2.5	0
544	Pain in intensive care after sternotomy is predictive for chronic thoracic pain. Critical Care, 2008, 12, P510.	2.5	2
545	Pharmacokinetics of oral melatonin in patients recovering from critical illness. Critical Care, 2008, 12, P511.	2.5	0
546	Current awareness of delirium in the ICU: a postal survey in The Netherlands. Critical Care, 2008, 12, P512.	2.5	0
547	Risk factors associated with delirium in a general ICU: role of S-100 protein. Critical Care, 2008, 12, P513.	2.5	ο

#	Article	IF	CITATIONS
548	Nicotine replacement therapy is associated with improved outcomes in critically ill smokers. Critical Care, 2008, 12, P514.	2.5	0
549	Translation, retranslation and validation of the Dutch Confusion Assessment Method for the Intensive Care Unit. Critical Care, 2008, 12, P515.	2.5	8
550	Efficacy of electrical muscle stimulation on preserving the muscle mass of critically ill patients. Critical Care, 2008, 12, P516.	2.5	1
551	End of life practices in India. Critical Care, 2008, 12, P517.	2.5	0
552	End of life care: communication $\hat{a} \in$ " a retrospective survey. Critical Care, 2008, 12, P518.	2.5	0
553	Care of terminally ill patients: an opinion survey among healthcare providers in the Middle East. Critical Care, 2008, 12, P519.	2.5	0
554	Prognostic factors of elderly patients admitted to an ICU. Critical Care, 2008, 12, .	2.5	0
555	Intensive care use and mortality in the very elderly patients. Critical Care, 2008, 12, P521.	2.5	0
556	Decisions to limit care: evaluation of newly graduated physicians during a selection process for medical residency in Brazil. Critical Care, 2008, 12, P522.	2.5	0
557	Interdisciplinary ethics consultation on the surgical ICU: indication 'on a gut level'?. Critical Care, 2008, 12, P523.	2.5	0
558	Safety assessment of the direct sequence spread spectrum wireless local area network with a medical device. Critical Care, 2008, 12, P524.	2.5	0
559	Consumption of ICU resources by long-stay patients does not change over time: 10-year observation in a teaching hospital in The Netherlands. Critical Care, 2008, 12, P525.	2.5	1
560	Microcosting study of ICU costs in three European countries. Critical Care, 2008, 12, P526.	2.5	3
561	Indication and use of chest X-ray scans in the ICU. Critical Care, 2008, 12, P527.	2.5	0
562	Technology in the ICU; the nurses' point of view. Critical Care, 2008, 12, P528.	2.5	0
563	Overflow critical care facility in a teaching hospital: how often do we use it?. Critical Care, 2008, 12, P529.	2.5	0
564	Visiting policies in Italian pediatric ICUs: a national survey. Critical Care, 2008, 12, P530.	2.5	0
565	Multidisciplinary educational needs assessment of critical care in community hospitals. Critical Care, 2008, 12, P531.	2.5	0

#	Article	IF	CITATIONS
566	Intensive care not confined to the bedspace: successfully implemented ventilation and monitoring solution for ICU intrahospital transport that is offering improvements in patient care. Critical Care, 2008, 12, P532.	2.5	0
567	Quantification and characterisation of work done by intensive care doctors outside the ICU. Critical Care, 2008, 12, P533.	2.5	0
568	Information management framework in adult critical care: experience from a large Canadian health region. Critical Care, 2008, 12, P534.	2.5	0
569	Serial evaluation of the Multiple Organ Dysfunction Score, Sequential Organ Failure Assessment and Logistic Organ Dysfunction scores to predict ICU mortality in mixed critically ill patients. Critical Care, 2008, 12, P535.	2.5	1
570	Impact of the opening of a ward-based noninvasive ventilation unit on critical care. Critical Care, 2008, 12, P536.	2.5	0
571	ICU admission during round time is associated with increased mortality. Critical Care, 2008, 12, P537.	2.5	0
572	Prognosis of patients with haematological malignancies admitted to the ICU. Critical Care, 2008, 12, P538.	2.5	0
573	Communication survey on use of cellphones versus pagers among anesthesiologists. Critical Care, 2008, 12, P539.	2.5	0
574	Online learning resources in emergency medicine for primary care professionals. Critical Care, 2008, 12, P540.	2.5	0
575	Simulation-based training on emergencies in cardiology: experience with 497 trainees. Critical Care, 2008, 12, P541.	2.5	0
576	Anidulafungin: advantage for the newcomer?. Expert Review of Clinical Pharmacology, 2008, 1, 207-216.	1.3	4
577	Micafungin activity against Candida albicans with diverse azole resistance phenotypes. Journal of Antimicrobial Chemotherapy, 2008, 62, 349-355.	1.3	19
578	Correlation of MIC with Outcome for <i>Candida</i> Species Tested against Caspofungin, Anidulafungin, and Micafungin: Analysis and Proposal for Interpretive MIC Breakpoints. Journal of Clinical Microbiology, 2008, 46, 2620-2629.	1.8	231
579	Micafungin for the prophylaxis and treatment ofCandidainfections. Expert Review of Anti-Infective Therapy, 2008, 6, 153-162.	2.0	12
580	Antifungal drugs. Side Effects of Drugs Annual, 2008, 30, 316-335.	0.6	1
581	Micafungin in the treatment of invasive candidiasis and invasive aspergillosis. Infection and Drug Resistance, 0, , 63.	1.1	4
582	Expansion of a recent class of broad-spectrum antifungal agents: the echinocandins. Microbiologia Medica, 2009, 24, .	0.3	0
583	Pharmacotherapy of <i>Candida</i> Infections with Echinocandins. Clinical Medicine Therapeutics, 2009, 1, CMT.S2311.	0.1	4

# 584	ARTICLE Review of the pharmacology and clinical studies of micafungin. Drug Design, Development and Therapy, 2009, 3, 295.	IF 2.0	CITATIONS 23
586	Micafungin: a sulfated echinocandin. Journal of Antibiotics, 2009, 62, 27-35.	1.0	55
587	Candida esophagitis complicated by an esophago-airway fistula: Report of a case. Surgery Today, 2009, 39, 972-978.	0.7	11
589	Echinocandins: The Newest Class of Antifungals. Annals of Pharmacotherapy, 2009, 43, 1647-1657.	0.9	168
590	Oral fungal infections. , 2009, , 501-508.		0
591	Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders. Leukemia and Lymphoma, 2009, 50, 92-100.	0.6	38
593	Micafungine. Journal De Mycologie Medicale, 2010, 20, 194-205.	0.7	2
594	Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection. HIV/AIDS - Research and Palliative Care, 2010, 2, 89.	0.4	40
595	Echinocandins: A ray of hope in antifungal drug therapy. Indian Journal of Pharmacology, 2010, 42, 9.	0.4	51
596	Micafungin in a nutshell: state of affairs on the pharmacological and clinicalÂaspects of the novel echinocandin. Therapy: Open Access in Clinical Medicine, 2010, 7, 555-563.	0.2	1
597	Management of oropharyngeal and esophageal candidiasis in patients with HIV infection. HIV Therapy, 2010, 4, 325-343.	0.6	2
598	Antifungals to treat <i>Candida albicans</i> . Expert Opinion on Pharmacotherapy, 2010, 11, 2037-2048.	0.9	58
600	Echinocandin Antifungal Drugs in Fungal Infections. Drugs, 2011, 71, 11-41.	4.9	324
601	Overview of treatment options for invasive fungal infections. Medical Mycology, 2011, 49, 1-20.	0.3	47
602	The comparison of solitary topical micafungin or fluconazole application in the treatment of Candida fungal keratitis. British Journal of Ophthalmology, 2011, 95, 1406-1409.	2.1	25
603	Systemic Antifungals. , 2011, , 99-122.		0
605	Evaluation of the safety and efficacy of micafungin in Japanese patients with deep mycosis: a post-marketing survey report. Journal of Infection and Chemotherapy, 2011, 17, 622-632.	0.8	18
606	Distribution of micafungin in the tissue fluids of patients with invasive fungal infections. Journal of Infection and Chemotherapy, 2011, 17, 731-734.	0.8	34

#	Article	IF	CITATIONS
607	Efficacy and safety of micafungin as an empirical therapy for invasive fungal infections in patients with hematologic disorders: a multicenter, prospective study. Annals of Hematology, 2011, 90, 1209-1217.	0.8	27
608	Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases. Expert Opinion on Drug Safety, 2011, 10, 171-183.	1.0	28
609	Clinical efficacy and safety of micafungin in Japanese patients with chronic pulmonary aspergillosis: a prospective observational study. Medical Mycology, 2011, 49, 1-6.	0.3	24
610	Advances in systemic antifungal therapy. Clinics in Dermatology, 2012, 30, 657-661.	0.8	9
611	ESCMID guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS. Clinical Microbiology and Infection, 2012, 18, 68-77.	2.8	81
612	Micafungin. Drugs, 2012, 72, 2141-2165.	4.9	33
613	Systemic Antifungal Agents. , 2012, , 1971-1977.		0
614	The Role of Micafungin and Anidulafungin in the Treatment of Systemic Fungal Infections: Applications and Patents for Two Novel Echinocandins. Recent Patents on Anti-infective Drug Discovery, 2012, 7, 1-7.	0.5	4
615	Pharmacological and Host Considerations Surrounding Dose Selection and Duration of Therapy with Echinocandins. Current Fungal Infection Reports, 2012, 6, 95-106.	0.9	0
616	How can we reduce hepatic veno-occlusive disease–related deaths after allogeneic stem cell transplantation?. Experimental Hematology, 2012, 40, 513-517.	0.2	24
617	Micafungin for candidiasis. Mycoses, 2012, 55, 8-12.	1.8	10
618	Safety of micafungin in prospective and retrospective clinical trials. Mycoses, 2012, 55, 58-64.	1.8	2
619	Efficacy and safety of micafungin as an empirical antifungal therapy for suspected fungal infection in neutropenic patients with hematological disorders. Annals of Hematology, 2012, 91, 449-457.	0.8	16
620	Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066). Infection, 2013, 41, 91-115.	2.3	37
621	Les échinocandinesÂ: mise au point. Journal Des Anti-infectieux, 2013, 15, 83-94.	0.1	0
622	Invasive candidiasis: update on current pharmacotherapy options and future perspectives. Expert Opinion on Pharmacotherapy, 2013, 14, 1515-1528.	0.9	27
623	Clinical Pharmacodynamic Index Identification for Micafungin in Esophageal Candidiasis: Dosing Strategy Optimization. Antimicrobial Agents and Chemotherapy, 2013, 57, 5714-5716.	1.4	28
624	Micafungin: an evidence-based review of its place in therapy. Core Evidence, 2014, 9, 27.	4.7	18

#	Article	IF	CITATIONS
625	Different doses of micafungin for prophylaxis of invasive fungal diseases in hematoâ€oncological highâ€risk patients: a webâ€based nonâ€interventional trial in four large university hospitals in <scp>G</scp> ermany. Transplant Infectious Disease, 2014, 16, 968-974.	0.7	9
626	<scp>EUCAST</scp> Technical Note on <i>Candida</i> and micafungin, anidulafungin and fluconazole. Mycoses, 2014, 57, 377-379.	1.8	38
627	Preparative Regimen Dosing for Hematopoietic Stem Cell Transplantation in Patients with Chronic Hepatic Impairment: Analysis of the Literature and Recommendations. Biology of Blood and Marrow Transplantation, 2014, 20, 622-629.	2.0	8
628	Drugs Active against Fungi, Pneumocystis, and Microsporidia. , 2015, , 479-494.e4.		8
629	Role of Echinocandins in Fungal Biofilm–Related Disease: Vascular Catheter–Related Infections, Immunomodulation, and Mucosal Surfaces. Clinical Infectious Diseases, 2015, 61, S622-S629.	2.9	28
630	Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: a meta-analysis of RCTs. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 651-659.	1.3	56
631	A Phase 2, Randomized, Double-Blind, Multicenter Trial To Evaluate the Safety and Efficacy of Three Dosing Regimens of Isavuconazole Compared with Fluconazole in Patients with Uncomplicated Esophageal Candidiasis. Antimicrobial Agents and Chemotherapy, 2015, 59, 1671-1679.	1.4	42
632	Pharmacokinetics of micafungin in subjects with severe hepatic dysfunction. European Journal of Drug Metabolism and Pharmacokinetics, 2015, 40, 285-293.	0.6	22
633	Antifungal Therapy. , 0, , .		3
634	Micafungin. , 2016, , 1010-1014.		0
636	Echinocandins. , 2016, , 6-14.		0
637	Clinical hepatotoxicity associated with antifungal agents. Expert Opinion on Drug Safety, 2017, 16, 1-17.	1.0	106
638	Short-term risk of liver and renal injury in hospitalized patients using micafungin: a multicentre cohort study. Journal of Antimicrobial Chemotherapy, 2016, 71, 2938-2944.	1.3	15
639	Antifungal Agents. Infectious Disease Clinics of North America, 2016, 30, 51-83.	1.9	264
640	Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2016, 62, e1-e50.	2.9	2,489
641	Pharmacokinetics of micafungin in patients with pre-existing liver dysfunction: A safe option for treating invasive fungal infections. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2016, 34, 652-654.	0.3	8
642	Echinocandins in antifungal pharmacotherapy. Journal of Pharmacy and Pharmacology, 2017, 69, 1635-1660.	1.2	98
643	Antifungal Drugs. , 2017, , 29-89.		1

#	Article	IF	CITATIONS
644	Antifungal Agents. , 2018, , 1532-1541.e3.		1
645	Infections in Hematopoietic Stem Cell Transplant Recipients. , 2018, , 195-230.		1
646	<i>Candida</i> infections in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clinical Transplantation, 2019, 33, e13623.	0.8	85
647	Efficacy and Safety of Echinocandins for the Treatment of Invasive Candidiasis in Children. Pediatric Infectious Disease Journal, 2019, 38, 42-49.	1.1	14
648	Treatment of invasive fungal infections in intensive care units with micafungin: The MYRIADE study. Mycoses, 2020, 63, 443-451.	1.8	1
649	Comparison of the Safety and Tolerance Profile of Micafungin with that of Other Echinocandins and Azoles in Patients with Pre-existing Child–Pugh B or C Liver Disease: A Case–Control Retrospective Study. Infectious Diseases and Therapy, 2020, 9, 151-163.	1.8	3
650	Other Diseases of the Esophagus. , 2021, , 238-244.e2.		0
651	Echinocandins. , 2021, , 438-448.		0
652	Mucocutaneous Manifestations in Gastrointestinal Disease. , 2021, , 2219-2248.		0
653	Novel Antifungal Therapies. , 2007, , 69-98.		2
654	Echinocandins. , 2011, , 95-112.		4
655	Invasive fungal infections in children: advances and perspectives. , 2007, , 405-472.		1
656	Systemic Antifungal Agents. , 2010, , 549-563.		5
657	Antifungals: Drug Class, Mechanisms of Action, Pharmacokinetics/Pharmacodynamics, Drug-Drug Interactions, Toxicity, and Clinical Use. , 0, , 343-371.		3
659	Classifying drugs in pregnancy. Australian Prescriber, 2014, 37, 38-40.	0.5	19
660	Comparison of echinocandin antifungals. Therapeutics and Clinical Risk Management, 2007, 3, 71-97.	0.9	164
661	Secondary Analysis of a Systematic Review: Are Antifungal Noninferiority Trials at Risk of Eroding Effectiveness Because of Biocreep?. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0162721.	1.4	3
662	Antifungal Agents. , 2008, , 1452-1460.		0

#	Article	IF	CITATIONS
663	ANTIFUNGAL AGENTS. , 2009, , 3271-3308.		0
664	Echinocandins for Prevention and Treatment of Invasive Fungal Infections. , 2009, , 219-242.		0
667	Echinocandins â $\in$ " Caspofungin, Anidulafungin and Micafungin. , 2010, , 1739-1762.		0
668	Esophagitis. , 2015, , 1248-1252.e2.		0
669	A Review of Esophagitis Due to Candida Species in Human Immunodeficiency Virus (HIV) Infected Patients. International Journal of Enteric Pathogens, 2018, 6, 84-88.	0.2	0
670	Mucocutaneous Manifestations in Gastrointestinal Disease. , 2020, , 1-31.		0
671	Methodological and reporting quality of non-inferiority randomized controlled trials comparing antifungal therapies: a systematic review. Clinical Microbiology and Infection, 2022, 28, 640-648.	2.8	3
672	Pharmacoeconomic Analysis of Micafungin (Mycamine) 100 mg and 150 mg Daily In the Treatment of Candidemia. P and T, 2009, 34, 196-9.	1.0	3
673	Micafungin in the treatment of invasive candidiasis and invasive aspergillosis. Infection and Drug Resistance, 2008, 1, 63-77.	1.1	10
674	Systemic antifungal therapy for oesophageal candidiasis – systematic review and meta-analysis of randomized controlled trials. International Journal of Antimicrobial Agents, 2022, 59, 106590.	1.1	0
675	Antifungal Agents. , 2023, , 1564-1573.e4.		0
676	Preclinical Pharmacokinetic/Pharmacodynamic Studies and Clinical Trials in the Drug Development Process of EMA-Approved Antifungal Agents: A Review. Clinical Pharmacokinetics, 0, , .	1.6	0